Get the Stockscreener App
19.56
0.61%
-0.12
Stoke Therapeutics Inc stock is traded at $19.56, with a volume of 1.15M.
It is down -0.61% in the last 24 hours and up +44.14% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$19.68
Open:
$19.73
24h Volume:
1.15M
Relative Volume:
1.66
Market Cap:
$1.07B
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-8.2532
EPS:
-2.37
Net Cash Flow:
$-82.68M
1W Performance:
+7.41%
1M Performance:
+44.14%
6M Performance:
+134.81%
1Y Performance:
+42.25%
1-Day Range:
$19.13
$19.91
1-Week Range:
$17.95
$19.91
52-Week Range:
$5.35
$19.91
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
19.56 | 1.01B | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Stoke Therapeutics Executives Sell Shares to Cover Tax Liabilities - TradingView
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - Eastern Progress
Stoke Therapeutics stock hits 52-week high at $18.61 - Investing.com India
Stoke Therapeutics stock hits 52-week high at $18.61 By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise 1.27% intraday after announcing inducement grants to new employees. - AInvest
Stoke Therapeutics shares fall 3.24% premarket after Purcell & Lefkowitz LLP announces shareholder investigation. - AInvest
Stoke Therapeutics' Strategic Stock Grants: Fueling Leadership Stability and Long-Term Value Creation in Biotech - AInvest
Stoke Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | STOK Stock News - GuruFocus
Stoke Therapeutics Inc. Approaches Psychological Resistance LevelWeekly Volume Report & Weekly Sector Rotation Insights - classian.co.kr
BTIG Maintains Buy Rating on Stoke Therapeutics with $28 Price Target - AInvest
Purcell & Lefkowitz LLP Investigates Stoke Therapeutics on Shareholder Breach of Fiduciary Duties - AInvest
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) - MarketScreener
Stoke Therapeutics price target lowered to $28 from $29 at BTIG - TipRanks
Stoke Therapeutics stock price target lowered to $28 at BTIG on Zorevunersen data - Investing.com
Watch for Trend Continuation in Stoke Therapeutics Inc. Next WeekQuarterly Trade Report & Free Expert Approved Momentum Trade Ideas - beatles.ru
Building trade automation scripts for Stoke Therapeutics Inc.Market Volume Summary & Safe Capital Growth Tips - Newser
Multi asset correlation models including Stoke Therapeutics Inc.July 2025 Selloffs & Real-Time Volume Analysis - Newser
Cantor Fitzgerald Has Positive View of STOK FY2025 Earnings - Defense World
Ranking Stoke Therapeutics Inc. among high performing stocks via toolsRisk Management & Free Expert Verified Stock Movement Alerts - Newser
Stoke Therapeutics Receives Buy Rating from Leerink Partners with $18 Price Target - AInvest
HC Wainwright Analysts Lift Earnings Estimates for STOK - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Defense World
Is Stoke Therapeutics Inc. stock ready for a breakoutMarket Sentiment Report & Low Risk Profit Maximizing Plans - Newser
What MACD and RSI say about Stoke Therapeutics Inc.July 2025 Analyst Calls & Expert Approved Momentum Ideas - Newser
Biogen Shares Surge 2.71% on $230M Volume Boosted by Pipeline Progress Ranks 444th in Market Activity - AInvest
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) By Investing.com - Investing.com Nigeria
Allan, general counsel, sells $205k in Stoke Therapeutics (STOK) - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Shareholders Are up 30% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
How Stoke Therapeutics Inc. stock performs during market volatility2025 Growth vs Value & Consistent Return Investment Signals - thegnnews.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate - simplywall.st
Stoke Therapeutics Inc. May Be Forming Higher Low — Chartwatchers Alert2025 Key Highlights & Capital Efficiency Focused Ideas - beatles.ru
Wedbush Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - Defense World
Stoke Therapeutics Inc. Stock Poised for Technical ComebackMarket Activity Recap & Daily Stock Momentum Reports - newsimpact.co.kr
Stocks With Rising Relative Price Strength: Stoke Therapeutics - MSN
Healthcare Stocks Under Analyst Spotlight: Lyra Therapeutics, Stoke Therapeutics, and Astria Therapeutics. - AInvest
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Given Buy Rating at Chardan Capital - Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Strong Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High on Analyst Upgrade - Defense World
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - MSN
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Stoke Therapeutics Skyrockets 25.57%—What’s Fueling This Biotech Surge? - AInvest
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics Launches Global Phase III Trial of Zorevunersen for Dravet Syndrome. - PharmiWeb.com
Stoke Therapeutics shares rise 3.10% premarket after dosing first patient in Phase 3 trial of Zorevunersen for Dravet Syndrome. - AInvest
Chardan Capital Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Promising Developments in Stoke Therapeutics’ Clinical Trials Support Buy Rating - TipRanks
Stoke Therapeutics: Promising Outlook with Strong Financial Position and Advancing Clinical Trials Justifies Buy Rating - TipRanks
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 14 '25 |
Option Exercise |
0.00 |
6,000 |
0 |
25,631 |
| Kaye Edward M. MD | Director |
Aug 14 '25 |
Option Exercise |
0.00 |
26,250 |
0 |
165,596 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 13 '25 |
Sale |
15.00 |
13,712 |
205,680 |
19,631 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):